STOCK TITAN
  1. Home
  2. News
  3. VTRS

Viatris Inc. - $VTRS STOCK NEWS

Welcome to our dedicated page for Viatris news (Ticker: $VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Viatris's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Viatris's position in the market.

News
Viatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva
Rhea-AI Summary
Viatris Inc. (VTRS) and Kindeva Drug Delivery L.P. launch Breyna™, the first generic version of AstraZeneca's Symbicort® with an Abbreviated New Drug Application (ANDA) approved by the U.S. Food and Drug Administration (FDA). Breyna is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD) and will be immediately available in both 80 mcg/4.5 mcg and 160 mcg/4.5 mcg dosage strengths. Viatris has also established a copay program to expand access to Breyna, offering eligible commercially-insured patients reduced out-of-pocket expenses on prescriptions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
partnership
-
News
Viatris to Report Second Quarter 2023 Financial Results on August 7, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
conferences earnings
-
News
Viatris Named to USA Today’s Inaugural List of America’s Climate Leaders 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
none
News
Viatris Named to USA Today's Inaugural List of America's Climate Leaders 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
none
-
News
Robert J. Coury to Transition from Executive Chairman of Viatris to Chairman Emeritus and Senior Strategic Advisor to the Board and Management at the End of the Year
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
none
-
News
Viatris Announces Appointment of Leo Groothuis to Company's Board of Directors
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
management
News
Viatris to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
conferences
-
News
Viatris Publishes Sustainability Report Showcasing 2022 Progress on Building Sustainable Access to Medicine
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
none
-
News
Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]
Rhea-AI Summary
Viatris Inc. reported total revenues of $3.73 billion, U.S. GAAP net earnings of $225 million, adjusted EBITDA of $1.34 billion, U.S. GAAP net cash provided by operating activities of $971 million, and free cash flow of $923 million for the first quarter of 2023. The company expects full-year total revenues, adjusted EBITDA, and free cash flow to be at the midpoint of its 2023 guidance ranges. Viatris returned approximately $400 million of capital to shareholders through dividends and share repurchases in the first quarter and paid down debt of $546 million. The company also declared a quarterly dividend of $0.12 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
earnings
News
Viatris and Mapi Pharma to Highlight Latest Results of Multiple Sclerosis Research at American Academy of Neurology 75th Annual Meeting
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
none
Stock VTRS logo
Viatris Inc.

Nasdaq:VTRS

VTRS Rankings

#711 Ranked by Market Cap
#2929 Ranked by Stock Gains
#707 Ranked by Dividends

VTRS Stock Data

12.39B
1.18B
0.35%
83.36%
3.06%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CANONSBURG

About VTRS

mylan is a global pharmaceutical company committed to setting new standards in healthcare. working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. we offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. in addition, we offer a wide range of antiretroviral therapies, upon which nearly 50% of hiv/aids patients in developing countries depend. we also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. learn more at mylan.com.